Lexeo wins FDA RMAT status for LX2020

Lexeo Therapeutics received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for LX2020, an investigational gene therapy targeting PKP2 arrhythmogenic cardiomyopathy, enhancing its regulatory pathway with benefits like accelerated review and priority status.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 6 Aug 2026 and 11 Aug 2026.